MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago.
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus: Riding The Bispecific Wave In Oncology
Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 million cash runway through 2028, allowing strategic R&D investments without immediate capital market pressures. Petosemtamab shows robust clinical data, receiving two FDA Breakthrough Therapy designations, indicating significant potential in treating HNSCC and other cancers.
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $1.09 per share a year ago.
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
Bizengri's recent approval gives MRUS the first approved therapy for NRG1+ cancers, which, I think, will be a valuable niche. Petosemtamab's recent Phase 2 data for HNSCC suggests it could also have blockbuster potential as long as its Phase 3 trials are successful as well. I also like MRUS's recent partnership with BHVN as it gives it optionality with new ADC programs that could have oncology applications.
Merus Scores Its First FDA Approval For Lung Cancer Drug
On Wednesday, the FDA approved Merus N.V.'s MRUS Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy.
Biotech Stock Boosted on Brand-New 'Buy' Rating
Biotech stock Merus NV (NASDAQ:MRUS) is up 3.4% at $44.40 at last glance, though pulling back a bit from its premarket surge, after Goldman Sachs initiated coverage with a "buy" rating.
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Merus is nearing a major milestone with zenocutuzumab's potential FDA approval for NRG1+ NSCLC/PDAC, with a PDUFA date of February 4, 2025. Petosemtamab, targeting 1st and 2nd-line HNSCC, shows promise with updated data to be presented at ESMO Asia Congress in December 2024. Financially stable with $782.9 million in cash, Merus has strategic partnerships with Gilead, Eli Lilly, Incyte, and Ono Pharmaceutical, funding operations into 2028.
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.43 per share a year ago.
Merus: Great European Oncology Developer, But Properly Valued
Merus NV has seen a significant increase in market cap from $852mn to $3.46bn in the past year. Merus is a leader in developing multispecific antibodies with promising lead candidates petosemtamab and zenocutuzumab targeting various cancers. Merus has strong financials, and partnerships with major companies like Gilead, Incyte, and Eli Lilly, but faces risks due to its current valuation and assumptions about pipeline success.
Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago.
